CAN Opposes CMS’ Decision Regarding Monoclonal Antibodies

Person Holding Alzheimer's Drugs

Representing millions of family caregivers of loved ones with Alzheimer’s disease, Caregiver Action Network (CAN) is strongly disappointed with CMS’ decision regarding Coverage with Evidence Development (CED) for potential life-changing Alzheimer’s drugs. We believe that this decision will deny Medicare beneficiaries access to a ground-breaking therapy where there are no alternatives.

This goes against Caregiver Action Network’s mission to provide access to new FDA-approved treatments. Caregivers and their loved ones need these therapies. We believe this decision undermines the FDA approval process. CMS has never refused to cover an FDA-approved drug based on its on-label use. Nor has CMS denied coverage of an entire class of drugs based on one drug’s safety and efficacy profile. We strongly urge CMS to reverse this unfortunate decision.

About CAN

Caregiver Action Network (www.CaregiverAction.org) is the nation’s leading family caregiver organization working to improve the quality of life for more than 90 million Americans who care for loved ones with chronic conditions, disabilities, disease, or the frailties of old age.

Caregiver Action Network serves a broad spectrum of family caregivers, from parents of children with health needs to friends of wounded soldiers. CAN supports young couples facing MS and adult children caring for parents with Alzheimer’s disease.

CAN reaches caregivers on multiple platforms. The National Family Caregivers Association is a 501(c)(3) non-profit organization. It offers free education, peer support, and resources to family caregivers nationwide.